Horizon Space Acquisition II Corp.
HSPT
NASDAQ Global Market5.86
USD
+1.42
- -
ISIN
KYG8191L1169
CUSIP
G8191L116
Return %
Stock
S&P500
1Y
-42.83
15.98
3Y
-41.52
62.25
5Y
-41.52
67.55
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Ming Yu Li
- Full Time Employees
- 2
- Sector
- Financial Services
- Industry
- Financial - Conglomerates
- Address
- 1412 Broadway New York NY United States of America 10018
- IPO Date
- Feb 5, 2025
- Website
- healthspace.com
- Similar Companies
- Business
- Horizon Space Acquisition II Corp. is a blank check company (special purpose acquisition company or SPAC) incorporated in the Cayman Islands in March 2023 and headquartered in New York, New York. The company was formed for the primary purpose of effectuating a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. Horizon Space Acquisition II Corp. does not have significant operations or generate revenue; instead, it seeks to identify and acquire or merge with a target business, with no limitation on industry or geographic region, although it has notable ties to China and may pursue opportunities in China, including Hong Kong and Macau. The company completed its initial public offering in November 2024, raising approximately $60 million through the issuance of 6 million units. Each unit comprises one ordinary share and one right to receive one-tenth of a share upon completion of an initial business combination. Maxim Group LLC acted as the sole book-running manager for the offering. In May 2025, Horizon Space Acquisition II Corp. entered into a definitive business combination agreement with SL Bio Ltd., a clinical-stage biomedical firm specializing in cellular and gene therapies targeting dermatological care and cancer recovery. This proposed reverse merger transaction, valued at approximately $5.7 billion, is expected to close in late 2025, subject to regulatory and shareholder approvals. Upon completion of this transaction, Horizon Space Acquisition II Corp. will become the surviving entity, listing SL Bio and its innovative cellular therapies for diseases including pancreatic cancer and glioblastoma on the Nasdaq. Leadership will include William Wang as CEO and Chairman, focusing on expanding SL Bio's products globally to deliver next-generation, affordable, personalized therapies. Horizon Space Acquisition II Corp. operates within the financial sector, specifically as a shell company and SPAC, targeting high-growth sectors through acquisition rather than direct production of goods or services. Its business strategy revolves around acquisition-led growth, with a clear recent strategic shift towards the biomedical sector through the SL Bio transaction. The company is led by CEO and Chairman Mingyu Li and CFO Min Zhai, headquartered at 1412 Broadway, 21st Floor, New York, NY 10018, United States. In summary, Horizon Space Acquisition II Corp. is a SPAC engaged in identifying and acquiring high-potential businesses, with its most recent major development being a pending reverse merger with SL Bio Ltd., signaling a strategic entry into the biomedical and cellular therapy markets.
SL BIO Ltd. and Horizon Space Acquisition II Announce Closing of Business Combination and Listing on the Nasdaq Global Market
Horizon Space Acquisition II Corp. Clarifies Redemption Process for Business Combination Shareholder Meeting and Extension Shareholder Meeting
Horizon Space Acquisition II Corp. Postponed the Extraordinary General Meeting to February 12, 2026 and Extended the Redemption Request Deadline
Deal Dispatch: Saks Faces A Luxury Liquidity Crisis, Soho House Gets Quiet
Horizon Space Acquisition II Corp. Announces Definitive Business Combination Agreement with SL Bio Ltd.